155 related articles for article (PubMed ID: 11590897)
41. Infrequent dosing of subcutaneous erythropoietin for the treatment of anemia in patients on CAPD.
Bunke M; Bartlett DK; Brier ME; Golper TA
Adv Perit Dial; 1993; 9():331-5. PubMed ID: 8105957
[TBL] [Abstract][Full Text] [Related]
42. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
Frankenfield DL; Johnson CA
Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
[TBL] [Abstract][Full Text] [Related]
43. A Prospective, Self-Controlled Pilot Study of the Efficacy of Roxadustat for Erythropoietin Hyporesponsiveness in Patients Requiring Chronic Ambulatory Peritoneal Dialysis.
Chen J; Li Z; Zhang H; Hu J; Wang J; Zhou H; Liu Y; Liu J; Yi B; Zhang W
J Ren Nutr; 2022 Sep; 32(5):595-604. PubMed ID: 34756787
[TBL] [Abstract][Full Text] [Related]
44. Randomized prospective study of the effect of increased dialytic dose on nutritional and clinical outcome in continuous ambulatory peritoneal dialysis patients.
Mak SK; Wong PN; Lo KY; Tong GM; Fung LH; Wong AK
Am J Kidney Dis; 2000 Jul; 36(1):105-14. PubMed ID: 10873879
[TBL] [Abstract][Full Text] [Related]
45. Factors affecting low values of serum albumin in CAPD patients.
Han DS; Lee SW; Kang SW; Choi KH; Lee HY; Cho EY; Lee JH
Adv Perit Dial; 1996; 12():288-92. PubMed ID: 8865921
[TBL] [Abstract][Full Text] [Related]
46. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD.
Axelsson J; Qureshi AR; Heimbürger O; Lindholm B; Stenvinkel P; Bárány P
Am J Kidney Dis; 2005 Oct; 46(4):628-34. PubMed ID: 16183417
[TBL] [Abstract][Full Text] [Related]
47. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
48. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
Pérez-García R; Rodríguez Benítez P; Jofre R; López-Gómez JM; Villaverde MT; Blanco A; Blanco S; Sánchez M
Nefrologia; 2007; 27(3):340-9. PubMed ID: 17725454
[TBL] [Abstract][Full Text] [Related]
49. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
50. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
Fang YW; Chang CH
Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
[TBL] [Abstract][Full Text] [Related]
51. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
[TBL] [Abstract][Full Text] [Related]
52. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
[TBL] [Abstract][Full Text] [Related]
53. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of intraperitoneal epoetin alfa in patients on peritoneal dialysis using an 8-hour "dry dwell" dosing technique.
Taylor CA; Kosorok MR; Zimmerman SW; Johnson CA
Am J Kidney Dis; 1999 Oct; 34(4):657-62. PubMed ID: 10516346
[TBL] [Abstract][Full Text] [Related]
55. The impact of residual renal function on quality of life in patients with peritoneal dialysis
.
Zhou W; Hu W; Han G; Wang H; Zhang J; Mei C
Clin Nephrol; 2018 Aug; 90(2):106-111. PubMed ID: 29932407
[TBL] [Abstract][Full Text] [Related]
56. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
57. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC
Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088
[TBL] [Abstract][Full Text] [Related]
58. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.
Richardson D; Lindley EJ; Bartlett C; Will EJ
Am J Kidney Dis; 2003 Sep; 42(3):551-60. PubMed ID: 12955684
[TBL] [Abstract][Full Text] [Related]
59. Importance of residual renal function in continuous ambulatory peritoneal dialysis: its influence on different parameters of renal replacement treatment.
López-Menchero R; Miguel A; García-Ramón R; Pérez-Contreras J; Girbés V
Nephron; 1999; 83(3):219-25. PubMed ID: 10529628
[TBL] [Abstract][Full Text] [Related]
60. Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project.
Bailie GR; Frankenfield DL; Prowant BF; McClellan W; Rocco MV
Am J Kidney Dis; 1999 Jun; 33(6):1187-9. PubMed ID: 10352214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
